Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Johnson & Johnson Secures EU Approval for TECVAYLI in Multiple Myeloma

Guavy AI Editorial Team
Instruments
JNJ
Share

Johnson & Johnson (JNJ) has secured European Commission approval for TECVAYLI (teclistamab) in combination with daratumumab as a treatment for adult patients with relapsed or refractory multiple myeloma.

The decision expands the approved indication for TECVAYLI in Europe, following Phase 3 data that demonstrated significant survival benefits compared to standard of care.

This expanded label adds a new therapeutic option within Johnson & Johnson's multiple myeloma portfolio and may influence its European oncology franchise over time.

Investors tracking Johnson & Johnson and broader oncology trends may also want to review peers gaining traction in healthcare-focused AI through 41 healthcare AI stocks.

More on Stocks

Stocks just now

Alphabet Shines in Q2, Reddit's Growth Falls Short

Stocks 1m ago

Nasdaq Tumbles as Micron Falls 6%, Nvidia's Earnings Loom

Stocks 1m ago

Alphabet's Strong Search, Cloud, and AI Growth Draws Market Attention

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy